Bauer L, van Riel D (2023) Do SARS-CoV-2 variants Differ in their neuropathogenicity? MBio. 14(1):e0292022

Bauer L, Rissmann M, Benavides FFW, Leijten L, van Run P, Begeman L et al (2022) In vitro and in vivo differences in neurovirulence between D614G, Delta and Omicron BA.1 SARS-CoV-2 variants. Acta Neuropathol Commun 10(1):124

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bendella Z, Widmann CN, Layer JP, Layer YL, Haase R, Sauer M et al (2023) Brain volume changes after COVID-19 compared to healthy controls by Artificial Intelligence-based MRI volumetry. Diagnostics (Basel). 13(10)

Chen Y-R, Ugiliweneza B, Burton E, Woo SY, Boakye M, Skirboll S (2017) The effect of postoperative infection on survival in patients with glioblastoma. J Neurosurg 127(4):807–811

Article  PubMed  Google Scholar 

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722

Article  CAS  PubMed  Google Scholar 

Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH et al (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379(2):150–161

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with Glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134(3):495–504

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I et al (2021) Oncolytic HSV-1 G207 immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 384(17):1613–1622

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friendlander AH, Ettinger RL (2009) Karnofsky performance status scale. Spec Care Dentist 29(4):147–148

Article  PubMed  Google Scholar 

Galldiks N, Kocher M, Langen K-J (2017) Pseudoprogression after glioma therapy: an update. Expert Rev Neurother 17(11):1109–1115

Article  CAS  PubMed  Google Scholar 

Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, Patiño-García A, Dobbs J, Gonzalez-Huarriz M et al (2022) Oncolytic DNX-2401 Virus for Pediatric diffuse intrinsic pontine glioma. N Engl J Med 386(26):2471–2481

Article  PubMed  Google Scholar 

Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA et al (2016) Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. Neuro Oncol 18(12):1664–1672

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O’Brien BJ et al (2024) Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: a retrospective case-control study. Neurooncol Pract 11(4):475–483

PubMed  Google Scholar 

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678–688

Article  CAS  PubMed  Google Scholar 

Hounchonou HF, Bajgora G, Esmaeilzadeh M, Hartmann C, Krauss JK (2024) Surgical site infections after glioblastoma surgery: boon or bane? J Cancer Res Clin Oncol 150(2):36

Article  PubMed  PubMed Central  Google Scholar 

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS et al (2018) Phase I study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36(14):1419–1427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Fèvre C, Lhermitte B, Ahle G, Chambrelant I, Cebula H, Antoni D et al (2021) Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review: part 1 - Molecular, morphological and clinical features. Crit Rev Oncol Hematol 157:103188

Article  PubMed  Google Scholar 

Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y (2024) Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol 17(1):31. https://doi.org/10.1186/s13045-024-01544-7. Published 2024 May 8

Article  PubMed  PubMed Central  Google Scholar 

Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A et al (2023) Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623(7985):157–166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Look T, Puca E, Bühler M et al (2023) Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. Sci Transl Med 15(697):eadf2281. https://doi.org/10.1126/scitranslmed.adf2281

Article  CAS  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. https://doi.org/10.1093/neuonc/noab106

Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK (2015) Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol 123(1):141–150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU et al (2017) The neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 19(5):625–635

Article  PubMed  PubMed Central  Google Scholar 

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C et al (2017) Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. N Engl J Med 376(11):1027–1037

Article  CAS  PubMed  Google Scholar 

Schwabenland M, Salié H, Tanevski J, Killmer S, Lago MS, Schlaak AE et al (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity 54(7):1594–1610e11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solár P, Mackerle Z, Hendrych M, Pospisil P, Lakomy R, Valekova H et al (2022) Prolonged survival in patients with local chronic infection after high-grade glioma treatment: two case reports. Front Oncol 12:1073036

Article  PubMed  PubMed Central  Google Scholar 

Suarez-Meade P, Watanabe F, Ruiz-Garcia H, Rafferty SB, Moniz-Garcia D, Schiapparelli PV et al (2023) SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models. J Neurooncol 161(1):67–76

Article  CAS  PubMed  PubMed Central  Google Scholar 

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J et al (2022) Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28(8):1630–1639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vogel MME, Wagner A, Gempt J, Krenzlin H, Zeyen T, Drexler R et al (2023) Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations. Sci Rep 13(1):2766

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18(10):1434–1441

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang T, Liu D, Fang S, Ma W, Wang Y (2022) Cytomegalovirus and glioblastoma: a review of the biological associations and therapeutic strategies. J Clin Med 11:17

Article